New combo therapy aims to save kidneys in High-Risk cancer patients
NCT ID NCT07504939
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a kidney-sparing approach for people with high-risk upper tract urothelial carcinoma, a cancer in the kidney or ureter. Instead of removing the whole kidney, participants get endoscopic surgery, targeted radiotherapy, and two drugs (disitamab vedotin and toripalimab). The goal is to see if this combination can prevent the cancer from coming back while keeping the kidney working. The trial plans to enroll 36 adults with HER2-positive tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
disitamab vedotin and toripalimab
What this could lead to
If successful, this could offer a way to treat high-risk upper tract urothelial carcinoma without removing the kidney, preserving kidney function while controlling the cancer.
What could go wrong
This is a small, early-phase study with only 36 participants, so results may not apply broadly. The combination of treatments may cause side effects, and the cancer could still return.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UPPER TRACT UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Departmeng of Urology, Peking University First Hospital
Beijing, China